Glaucoma stent approved

June 26, 2012
Glaucoma stent approved

(HealthDay) -- An ocular stent that's designed to reduce inner-eye pressure among people with mild or moderate open-angle glaucoma has been approved by the U.S. Food and Drug Administration.

The iStent Trabecular Micro-Bypass Stent System is sanctioned for people with the disease who also have a cataract. The stent, along with surgery to remove the cataract, is designed to prevent damage to the caused by high pressure inside the eye. Open-angle glaucoma, which causes this build-up of pressure, is among the leading causes of vision loss and blindness, the FDA said in a news release.

The iStent is a small titanium tube that's designed to restore the natural draining of fluid from the eye, potentially decreasing intraocular pressure. The device was clinically studied among 239 people. Because the stent was used in cases where also was performed, complications -- including the stent becoming blocked -- could not be attributed solely to either the stent or the surgery, the agency said.

The iStent system is manufactured by Glaukos Corp., based in Laguna Hills, Calif.

Explore further: After 55 years, surgery restores sight

More information: Medline Plus has more about glaucoma.


Related Stories

After 55 years, surgery restores sight

June 17, 2011
After being hit in the eye by a stone, a detached retina left a man blind in his right eye. Despite surgery to remove a cataract when the man was 23, which temporarily restored light perception, the patient was completely ...

A new stent design may put patients at risk

November 17, 2011
Some stents that keep blood vessels open to treat heart disease are poorly designed to resist shortening, according to publications in the Journal of Interventional Cardiology. A case report published in the journal by Dr. ...

Recommended for you

Research reveals biological mechanism of a leading cause of childhood blindness

November 16, 2017
Scientists at the Virginia Tech Carilion Research Institute (VTCRI) have revealed the pathology of cells and structures stricken by optic nerve hypoplasia, a leading cause of childhood blindness in developed nations.

Genetic treatment for blindness may soon be reality

November 11, 2017
Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting ...

Study finds donor corneas can be safely preserved for longer period

November 10, 2017
Results from a large, national clinical trial show that corneal donor tissue can be safely stored for 11 days without negatively impacting the success of transplantation surgery to restore vision in people with diseases of ...

Exploring the genetics of glaucoma and retinal development

November 10, 2017
Guillermo Oliver, PhD, the Thomas D. Spies Professor of Lymphatic Metabolism, recently published two studies related to the eye, one on retinal formation and the other on the genetics behind glaucoma.

Scientists discover potential treatment to stop glaucoma in its tracks

November 6, 2017
Vision scientists at the University of California, Berkeley, and the University of Toronto have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma, ...

New focus on correcting refractive vision

October 25, 2017
While doctors take delight in solving the common issue of refractive vision error by prescribing eye glasses, Flinders University researchers have found that many patients are upset with this solution and claim it affects ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.